Literature DB >> 16984875

Pharmacokinetics and pharmacodynamics of antifungals.

David Andes1.   

Abstract

Application of pharmacodynamic principles to antifungal drug therapy of Candida and Aspergillus infections has provided and understanding of the relationship between drug dosing and treatment efficacy. Observations of the pharmacodynamics of triazoles and AmB have correlated with the results of clinical trials and have proven useful for validation of in vitro susceptibility breakpoints. Although there remain many unanswered questions regarding antifungal pharmacodynamics, available data suggest usefulness in the application of pharmacodynamics to antifungal clinical development. Future application of these principles should aid in the design of optimal combination antifungal therapies.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16984875     DOI： 10.1016/j.idc.2006.06.007

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN： 0891-5520            Impact factor:   5.982


  27 in total

Review 1.  Triazole antifungal agents in invasive fungal infections: a comparative review.

Authors:  Cornelia Lass-Flörl
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

2.  Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Joseph Meletiadis; Rafal Al-Saigh; Aristea Velegraki; Thomas J Walsh; Emmanuel Roilides; Loukia Zerva
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

3.  Association of fluconazole pharmacodynamics with mortality in patients with candidemia.

Authors:  Maiken C Arendrup; Manuel Cuenca-Estrella; J Peter Donnelly; Cornelia Lass-Flörl; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2009-06       Impact factor: 5.191

4.  VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model.

Authors:  E P Garvey; W J Hoekstra; W R Moore; R J Schotzinger; L Long; M A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2015-01-20       Impact factor: 5.191

5.  Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy.

Authors:  Silke Gastine; William Hope; Georg Hempel; Ruta Petraitiene; Vidmantas Petraitis; Diana Mickiene; John Bacher; Thomas J Walsh; Andreas H Groll
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

6.  Pharmacodynamics of Voriconazole against Wild-Type and Azole-Resistant Aspergillus flavus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis.

Authors:  Shivaprakash M Rudramurthy; Seyedmojtaba Seyedmousavi; Manpreet Dhaliwal; Arunaloke Chakrabarti; Jacques F Meis; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

7.  Management of invasive candidiasis in the intensive care unit.

Authors:  E Geoffrey Playford; Jeff Lipman; Tania C Sorrell
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

8.  Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis.

Authors:  Alexander J Lepak; Karen Marchillo; Jaimie Vanhecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

9.  Aerosolized Delivery of Antifungal Agents.

Authors:  Jennifer Le; Daryl S Schiller
Journal:  Curr Fungal Infect Rep       Date:  2010-04-13

10.  Propensity Score Analysis of the Role of Initial Antifungal Therapy in the Outcome of Candida glabrata Bloodstream Infections.

Authors:  M Puig-Asensio; M Fernández-Ruiz; J M Aguado; P Merino; D Lora-Pablos; J Guinea; P Martín-Dávila; M Cuenca-Estrella; B Almirante
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.